Euho Pharma, a wholly-owned subsidiary of Biositu, and South Korea’s ISU ABXIS to develop trispecific antibodies based on the YH003 sequence
BEIJING & SEOUL, South Korea--(BUSINESS WIRE)--Eucure Biopharma, a China-based clinical-stage biotechnology company focused on the development of antibody therapeutics, announced today that it has entered into a collaborative agreement with ISU ABXIS Co., Ltd. (KOSDAQ: 086890), a Korea-based clinical stage company developing immuno-oncology drugs.
(Reuters) - A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs’ misuse of confidential records they obtained through related litigation.
Isu Abxis, ranked first for two consecutive years in the Algerian Gaucher disease treatment bidding